Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• RAC1^P29S is a common melanoma mutation linked to poor prognosis and treatment resistance.
• Understanding RAC1-driven signaling is crucial for identifying new therapeutic targets in melanoma.
• Current knowledge of RAC1's role in tumorigenesis and its downstream effects is limited.

Purpose of the Study:

• To investigate the molecular signaling pathways affected by RAC1^P29S mutations in melanoma.
• To identify novel therapeutic targets for RAC1^P29S-mutant melanoma.
• To evaluate the efficacy of targeting CDK9 in combination with immunotherapy.

Main Methods:

• Generated an inducible RAC1^P29S expression melanocytic cell line.
• Utilized RNA-sequencing (RNA-seq) and multiplexed kinase inhibitor beads with mass spectrometry (MIBs/MS) for proteogenomic analysis.
• Conducted in vitro proliferation assays and in vivo tumor growth studies.

Main Results:

• Proteogenomic analysis identified CDK9 as a specific target in RAC1^P29S-mutant melanoma cells.
• CDK9 inhibition reduced proliferation of RAC1^P29S-mutant melanoma cells in vitro.
• CDK9 inhibition increased PD-L1 and MHC Class I expression on melanoma cells.
• Combined CDK9 inhibition and anti-PD-1 therapy significantly inhibited tumor growth in RAC1^P29S-mutant melanoma models in vivo.

Conclusions:

• CDK9 is a novel therapeutic target for RAC1-driven melanoma.
• Targeting CDK9 can enhance the efficacy of anti-PD-1 immunotherapy in RAC1^P29S-mutant melanoma.
• This study provides a rationale for clinical investigation of CDK9 inhibitors in combination with immunotherapy for melanoma patients with RAC1 mutations.